{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:31:34Z","timestamp":1792643494012,"version":"4.5.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:p>This cohort study evaluates the incidence of cataract surgery among patients receiving mirvetuximab soravtansine to treat ovarian cancer.<\/jats:p>","DOI":"10.1001\/jamanetworkopen.2026.14557","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:00:36Z","timestamp":1779375636000},"page":"e2614557","source":"Crossref","is-referenced-by-count":1,"title":["Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery"],"prefix":"10.1001","volume":"9","author":[{"given":"Jordyn F.","family":"Silverstein","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smick","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, David Geffen School of Medicine University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Tsui","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladunni","family":"Alomaja","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hong","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Medicine Statistics Core, David Geffen School of Medicine at University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, David Geffen School of Medicine University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Slamon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Chase","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, David Geffen School of Medicine University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"zld260078r1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","article-title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.","volume":"191","author":"Moore","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"23","key":"zld260078r2","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRa-positive, platinum-resistant ovarian cancer.","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"zld260078r3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FRa-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.","volume":"36","author":"Alvarez Secord","year":"2025","journal-title":"Ann Oncol"},{"issue":"7","key":"zld260078r4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1200\/OP-24-00735","article-title":"Incomplete toxicity reporting and use of toxicity-minimizing language in phase III oncology trials.","volume":"21","author":"Miller","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"zld260078r5","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine.","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"zld260078r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19366","article-title":"Cataract development among pediatric patients with uveitis.","volume":"7","author":"Hsu","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849177\/silverstein_2026_ld_260078_1778612671.56295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:00:36Z","timestamp":1779375636000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.14557","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}